Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Y-mAbs Therapeutics, Inc. - Common Stock (NQ: YMAB )

5.250 +0.400 (+8.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Analyst Ratings for Y-mAbs Therapeutics
Via Benzinga
Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful
Via Benzinga
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
From Kirby McInerney LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR NOTICE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Y-mAbs Class Action Lawsuit - YMAB
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce
Via Benzinga
NASDAQ:YMAB Investor Alert: Investigation over Possible Securities Laws Violations by Y-mAbs Therapeutics, Inc
San Diego, CA -- (SBWIRE) -- 11/18/2022 -- Y-mAbs Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Lost Money in Y-mAbs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Lost Money in Y-mABs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Looking Into Y-mAbs Therapeutics's Recent Short Interest
Y-mAbs Therapeutics's (NASDAQ:YMAB) short percent of float has fallen 16.88% since its last report. The company recently reported that it has 3.08 million shares sold short, which is 8.47% of all... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 85 stocks hit new 52-week lows. 
Via Benzinga
ON Semiconductor, Global Payments And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Lost Money in Y-mAbs Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product... 
Via Benzinga
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – YMAB
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.